Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma

समान संसाधन

• Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer
  द्वारा: Hong, David, और अन्य
  प्रकाशित: (2016)
• Dose‐finding study of the checkpoint kinase 1 inhibitor, prexasertib, in Japanese patients with advanced solid tumors
  द्वारा: Iwasa, Satoru, और अन्य
  प्रकाशित: (2018)
• Broad spectrum activity of the checkpoint kinase 1 inhibitor prexasertib as a single agent or chemopotentiator across a range of preclinical pediatric tumor models
  द्वारा: Lowery, Caitlin D., और अन्य
  प्रकाशित: (2018)
• Risk of Ipsilateral and Contralateral Cancer in BRCA Mutation Carriers with Breast Cancer
  द्वारा: Green, Leila, और अन्य
  प्रकाशित: (2011)
• Whole Genome Sequencing in Cancer Clinics
  द्वारा: Chen, Ken, और अन्य
  प्रकाशित: (2014)